InMode Ltd. (NASDAQ: INMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 11.82 | EPS (ttm) | 1.23 | Insider Own | 15.38% | Shs Outstand | 57.48M | Perf Week | -1.56% |
| Market Cap | 835.77M | Forward P/E | 10.60 | EPS next Y | 1.37 | Insider Trans | 0.00% | Shs Float | 48.09M | Perf Month | -3.00% |
| Enterprise Value | 338.77M | PEG | 2.07 | EPS next Q | 0.32 | Inst Own | - | Short Float | 4.88% | Perf Quarter | 8.83% |
| Income | 78.00M | P/S | 2.23 | EPS this Y | 5.37% | Inst Trans | - | Short Ratio | 3.85 | Perf Half Y | 8.10% |
| Sales | 375.00M | P/B | 1.33 | EPS next Y | 5.86% | ROA | 10.76% | Short Interest | 2.35M | Perf YTD | -1.02% |
| Book/sh | 10.94 | P/C | 1.67 | EPS next 5Y | 5.70% | ROE | 11.80% | 52W High | 16.74 -13.14% | Perf Year | -2.81% |
| Cash/sh | 8.72 | P/FCF | 9.79 | EPS past 3/5Y | -8.88% 9.95% | ROIC | 9.20% | 52W Low | 12.72 14.31% | Perf 3Y | -60.33% |
| Dividend Est. | - | EV/EBITDA | 4.03 | Sales past 3/5Y | -6.59% 12.43% | Gross Margin | 76.52% | Volatility | 1.54% 1.33% | Perf 5Y | -78.77% |
| Dividend TTM | - | EV/Sales | 0.90 | EPS Y/Y TTM | -45.33% | Oper. Margin | 18.47% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.28 | Sales Y/Y TTM | -5.06% | Profit Margin | 20.69% | RSI (14) | 35.11 | Recom | 2.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.18 | EPS Q/Q | -25.53% | SMA20 | -2.28% | Beta | 2.02 | Target Price | 19.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 0.00% | SMA50 | -3.58% | Rel Volume | 0.67 | Prev Close | 14.58 |
| Employees | 660 | LT Debt/Eq | 0.01 | Earnings | Oct 28 | SMA200 | 0.97% | Avg Volume | 615.22K | Price | 14.54 |
| IPO Date | Aug 08, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.16% 0.74% | Net Debt/EBITDA | -4.65 | Volume | 413,627 | Change | -0.27% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-07-26 | Reiterated | Barclays | Overweight | $27 → $19 |
| Feb-11-26 | Reiterated | Robert W. Baird | $16 → $17 | |
| Dec-17-25 | Reiterated | Canaccord Genuity | Hold | $16 → $15 |
| Apr-29-25 | Downgrade | BTIG | Buy → Neutral | |
| Apr-14-25 | Reiterated | Jefferies | Hold | $19 → $15 |
| Oct-16-24 | Reiterated | BTIG | $25 | |
| Jul-23-24 | Downgrade | Jefferies | Buy → Hold | $19 |
| Jul-12-24 | Reiterated | Canaccord Genuity | Hold | $22 → $16 |
| May-03-24 | Reiterated | UBS | Neutral | $20 |
| Nov-03-23 | Downgrade | UBS | Buy → Neutral |
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 375 | 370 | 395 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 88 | 80 | 78 | — | — | — | — | — | — | |
| Gross Profit | 287 | 291 | 317 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 204 | 192 | 191 | — | — | — | — | — | — | |
| Research and Development | 16 | 13 | 13 | — | — | — | — | — | — | |
| Other Operating Expense | -4 | 1 | 1 | — | — | — | — | — | — | |
| Operating Income | 69 | 85 | 113 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 25 | 31 | — | — | — | — | — | — | |
| Net Income Before Taxes | 91 | 110 | 143 | — | — | — | — | — | — | |
| Income Taxes | 14 | 16 | -38 | — | — | — | — | — | — | |
| Consolidated Net Income | 78 | 94 | 181 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 78 | 94 | 181 | — | — | — | — | — | — | |
| Net Income | 78 | 94 | 181 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.25 | 1.45 | 2.29 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.25 | 1.45 | 2.29 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.23 | 1.43 | 2.25 | — | — | — | — | — | — | |
| EBITDA | 84 | 111 | 144 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 11.82 | 10.27 | 7.42 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.29 | 2.58 | 3.34 | — | — | — | — | — | — | |
| Gross Margin | 76.53 | 78.65 | 80.25 | — | — | — | — | — | — | |
| Operating Margin | 18.40 | 22.97 | 28.61 | — | — | — | — | — | — | |
| Net Margin | 20.80 | 25.41 | 45.82 | — | — | — | — | — | — | |
| Shares Outstanding | 59 | 65 | 79 | — | — | — | — | — | — | |
| Market Capitalization | 858 | 955 | 1,319 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Oct 22 '10 | Buy | 8.22 | 1,339 | 11,007 | 1,322,396 | Oct 22 |
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Oct 21 '10 | Buy | 8.21 | 4,300 | 35,314 | 1,321,057 | Oct 22 |
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Oct 20 '10 | Buy | 8.20 | 3,528 | 28,930 | 1,316,757 | Oct 22 |
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Oct 04 '10 | Buy | 8.04 | 3,360 | 27,014 | 1,313,229 | Oct 05 |
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Oct 01 '10 | Buy | 8.34 | 15,000 | 125,100 | 1,309,869 | Oct 05 |
| BlueLine Capital Partners III, LP | 10% Owner | Sep 30 '10 | Buy | 9.27 | 5,802 | 53,785 | 1,294,869 | Sep 30 |
| BlueLine Capital Partners III, LP | 10% Owner | Sep 28 '10 | Buy | 9.09 | 1,500 | 13,635 | 1,289,067 | Sep 30 |
| BlueLine Capital Partners III, LP | 10% Owner | Sep 27 '10 | Buy | 9.02 | 5,058 | 45,623 | 1,285,567 | Sep 30 |
| BlueLine Catalyst Fund IX, L.P. | 10% Owner | Sep 20 '10 | Buy | 9.03 | 8,454 | 76,340 | 1,282,509 | Sep 22 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 16 '10 | Buy | 9.09 | 2,000 | 18,180 | 1,274,055 | Sep 16 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 15 '10 | Buy | 9.02 | 5,297 | 47,779 | 1,272,055 | Sep 16 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 14 '10 | Buy | 9.08 | 2,800 | 25,426 | 1,266,758 | Sep 16 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 13 '10 | Buy | 9.12 | 5,374 | 49,011 | 1,263,958 | Sep 13 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 10 '10 | Buy | 9.15 | 6,700 | 61,305 | 1,258,584 | Sep 13 |
| BlueLine Capital Partners, L.P. | 10% Owner | Sep 03 '10 | Buy | 9.10 | 800 | 7,280 | 1,251,884 | Sep 13 |